Engineering and Characterisation of Novel Nanomedicine Formulations, 2nd Edition

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: 30 April 2024 | Viewed by 2462

Special Issue Editors

Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain
Interests: antimicrobial agents; breast cancer; cannabinoids; drug delivery; drug targeting; in situ-forming implants; nanomedicine; ovarian cancer; polymers
Special Issues, Collections and Topics in MDPI journals
Departamento de Parasitología, Facultad de Farmacia, Universidad Complutense de Madrid, 28040 Madrid, Spain
Interests: parasitology; leishmania; pharmacokinetics; immunology
Special Issues, Collections and Topics in MDPI journals
School of Pharmacy, University of Nottingham, University Park, Nottingham, NG7 2RD, UK
Interests: nanomedicine; antifungal therapy; liposomes; microfluidics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are pleased to invite you to contribute to our Special Issue in the engineering and characterisation of novel nanomedicines. Nanomedicine has been a hot topic in formulation science in the last few decades regarding selectively delivering drugs to target tissues. Nanomedicines can modify drug release and encapsulate poorly soluble drugs, allowing a selective targeting and minimising adverse effects. This is of key importance in antitumoral and anti-infectious therapies, in which an undesired drug release can lead to severe damage in healthy tissues. Moreover, they protect drugs from degradation, allowing the delivery of RNA. This Special Issue aims to highlight the most novel nano-approaches in the treatment of cancer and infectious diseases. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: nanoparticles, liposomes, nanocapsules and drug targeting, applied to anticancer and anti-infectious therapies.

We look forward to receiving your contributions.

Dr. Ana Isabel Fraguas-Sánchez
Prof. Dr. Francisco Bolás-Fernández
Dr. Raquel Fernández García
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanoparticles
  • liposomes
  • solid lipid nanocapsules
  • drug targeting
  • cancer
  • infectious diseases
  • nanovaccines

Related Special Issue

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

31 pages, 5090 KiB  
Article
Transferrin-Bearing, Zein-Based Hybrid Lipid Nanoparticles for Drug and Gene Delivery to Prostate Cancer Cells
Pharmaceutics 2023, 15(11), 2643; https://doi.org/10.3390/pharmaceutics15112643 - 20 Nov 2023
Viewed by 935
Abstract
Gene therapy holds great promise for treating prostate cancer unresponsive to conventional therapies. However, the lack of delivery systems that can transport therapeutic DNA and drugs while targeting tumors without harming healthy tissues presents a significant challenge. This study aimed to explore the [...] Read more.
Gene therapy holds great promise for treating prostate cancer unresponsive to conventional therapies. However, the lack of delivery systems that can transport therapeutic DNA and drugs while targeting tumors without harming healthy tissues presents a significant challenge. This study aimed to explore the potential of novel hybrid lipid nanoparticles, composed of biocompatible zein and conjugated to the cancer-targeting ligand transferrin. These nanoparticles were designed to entrap the anti-cancer drug docetaxel and carry plasmid DNA, with the objective of improving the delivery of therapeutic payloads to prostate cancer cells, thereby enhancing their anti-proliferative efficacy and gene expression levels. These transferrin-bearing, zein-based hybrid lipid nanoparticles efficiently entrapped docetaxel, leading to increased uptake by PC-3 and LNCaP cancer cells and significantly enhancing anti-proliferative efficacy at docetaxel concentrations exceeding 1 µg/mL. Furthermore, they demonstrated proficient DNA condensation, exceeding 80% at polymer–DNA weight ratios of 1500:1 and 2000:1. This resulted in increased gene expression across all tested cell lines, with the highest transfection levels up to 11-fold higher than those observed with controls, in LNCaP cells. These novel transferrin-bearing, zein-based hybrid lipid nanoparticles therefore exhibit promising potential as drug and gene delivery systems for prostate cancer therapy. Full article
Show Figures

Figure 1

Review

Jump to: Research

32 pages, 4572 KiB  
Review
Exploiting Pharma 4.0 Technologies in the Non-Biological Complex Drugs Manufacturing: Innovations and Implications
Pharmaceutics 2023, 15(11), 2545; https://doi.org/10.3390/pharmaceutics15112545 - 28 Oct 2023
Viewed by 1248
Abstract
The pharmaceutical industry has entered an era of transformation with the emergence of Pharma 4.0, which leverages cutting-edge technologies in manufacturing processes. These hold tremendous potential for enhancing the overall efficiency, safety, and quality of non-biological complex drugs (NBCDs), a category of pharmaceutical [...] Read more.
The pharmaceutical industry has entered an era of transformation with the emergence of Pharma 4.0, which leverages cutting-edge technologies in manufacturing processes. These hold tremendous potential for enhancing the overall efficiency, safety, and quality of non-biological complex drugs (NBCDs), a category of pharmaceutical products that pose unique challenges due to their intricate composition and complex manufacturing requirements. This review attempts to provide insight into the application of select Pharma 4.0 technologies, namely machine learning, in silico modeling, and 3D printing, in the manufacturing process of NBCDs. Specifically, it reviews the impact of these tools on NBCDs such as liposomes, polymeric micelles, glatiramer acetate, iron carbohydrate complexes, and nanocrystals. It also addresses regulatory challenges associated with the implementation of these technologies and presents potential future perspectives, highlighting the incorporation of digital twins in this field of research as it seems to be a very promising approach, namely for the optimization of NBCDs manufacturing processes. Full article
Show Figures

Graphical abstract

Back to TopTop